메뉴 건너뛰기




Volumn 63, Issue 7, 2014, Pages 957-967

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients

Author keywords

Glimepiride; Insulin resistance; Oral fat load; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

GLIMEPIRIDE; GLUCAGON; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROINSULIN; RESISTIN; RETINOL BINDING PROTEIN 4; VASPIN; VILDAGLIPTIN;

EID: 84902546321     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.04.008     Document Type: Article
Times cited : (28)

References (53)
  • 1
    • 84859341109 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors: 3 years of experience
    • G. Derosa, and P. Maffioli Dipeptidyl peptidase-4 inhibitors: 3 years of experience Diabetes Technol Ther 14 4 2012 350 364
    • (2012) Diabetes Technol Ther , vol.14 , Issue.4 , pp. 350-364
    • Derosa, G.1    Maffioli, P.2
  • 2
    • 84869798707 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function
    • G. Derosa, A. Carbone, and A. D'Angelo et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function Expert Opin Pharmacother 13 17 2012 2433 2442
    • (2012) Expert Opin Pharmacother , vol.13 , Issue.17 , pp. 2433-2442
    • Derosa, G.1    Carbone, A.2    D'Angelo, A.3
  • 3
    • 84879592855 scopus 로고    scopus 로고
    • A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: The triple oral therapy
    • G. Derosa, A.F. Cicero, and I.G. Franzetti et al. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy Diabet Med 30 7 2013 846 854
    • (2013) Diabet Med , vol.30 , Issue.7 , pp. 846-854
    • Derosa, G.1    Cicero, A.F.2    Franzetti, I.G.3
  • 4
    • 77952316298 scopus 로고    scopus 로고
    • Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
    • G. Derosa, P. Maffioli, and S.A. Salvadeo et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients Metabolism 59 6 2010 887 895
    • (2010) Metabolism , vol.59 , Issue.6 , pp. 887-895
    • Derosa, G.1    Maffioli, P.2    Salvadeo, S.A.3
  • 5
    • 84878380125 scopus 로고    scopus 로고
    • Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients
    • G. Derosa, P.D. Ragonesi, and A. Carbone et al. Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients Pharmacol Res 73 2013 20 26
    • (2013) Pharmacol Res , vol.73 , pp. 20-26
    • Derosa, G.1    Ragonesi, P.D.2    Carbone, A.3
  • 6
    • 84870201257 scopus 로고    scopus 로고
    • Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: A 12-month, placebo-controlled study
    • G. Derosa, P.D. Ragonesi, and A. Carbone et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study Expert Opin Pharmacother 13 18 2012 2581 2591
    • (2012) Expert Opin Pharmacother , vol.13 , Issue.18 , pp. 2581-2591
    • Derosa, G.1    Ragonesi, P.D.2    Carbone, A.3
  • 7
    • 84861982613 scopus 로고    scopus 로고
    • Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients
    • G. Derosa, P.D. Ragonesi, and A. Carbone et al. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients Diabetes Technol Ther 14 6 2012 475 484
    • (2012) Diabetes Technol Ther , vol.14 , Issue.6 , pp. 475-484
    • Derosa, G.1    Ragonesi, P.D.2    Carbone, A.3
  • 8
    • 77955020170 scopus 로고    scopus 로고
    • Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients
    • G. Derosa, P. Maffioli, and I. Ferrari et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients Horm Metab Res 42 9 2010 663 669
    • (2010) Horm Metab Res , vol.42 , Issue.9 , pp. 663-669
    • Derosa, G.1    Maffioli, P.2    Ferrari, I.3
  • 9
    • 34347393269 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
    • Y.L. He, D. Serra, and Y. Wang et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus Clin Pharmacokinet 46 7 2007 577 588
    • (2007) Clin Pharmacokinet , vol.46 , Issue.7 , pp. 577-588
    • He, Y.L.1    Serra, D.2    Wang, Y.3
  • 10
    • 2442482515 scopus 로고    scopus 로고
    • Inhibition of dipeptidylpeptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes
    • B. Ahren, M. Landin-Olsson, and P.-A. Jansson et al. Inhibition of dipeptidylpeptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89 2004 2078 2084
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2078-2084
    • Ahren, B.1    Landin-Olsson, M.2    Jansson, P.-A.3
  • 11
    • 77954250537 scopus 로고    scopus 로고
    • The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
    • K.J. Hare, T. Vilsboll, and M. Asmar et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action Diabetes 59 2010 1765 1770
    • (2010) Diabetes , vol.59 , pp. 1765-1770
    • Hare, K.J.1    Vilsboll, T.2    Asmar, M.3
  • 12
    • 34147189738 scopus 로고    scopus 로고
    • The dipeptidylpeptidase-4 inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
    • B. Balas, M.R. Baig, and C. Watson et al. The dipeptidylpeptidase-4 inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients J Clin Endocrinol Metab 92 2007 1249 1255
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 1249-1255
    • Balas, B.1    Baig, M.R.2    Watson, C.3
  • 13
    • 58149465731 scopus 로고    scopus 로고
    • Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice
    • H. Duez, A.C. Smith, and C. Xiao et al. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice Endocrinology 150 1 2009 56 62
    • (2009) Endocrinology , vol.150 , Issue.1 , pp. 56-62
    • Duez, H.1    Smith, A.C.2    Xiao, C.3
  • 14
    • 84864802728 scopus 로고    scopus 로고
    • Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes
    • E. Muscelli, A. Casolaro, and A. Gastaldelli et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 97 8 2012 2818 2826
    • (2012) J Clin Endocrinol Metab , vol.97 , Issue.8 , pp. 2818-2826
    • Muscelli, E.1    Casolaro, A.2    Gastaldelli, A.3
  • 15
    • 39049141231 scopus 로고    scopus 로고
    • Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
    • K. Azuma, Z. Rádiková, and J. Mancino et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 93 2008 459 464
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 459-464
    • Azuma, K.1    Rádiková, Z.2    Mancino, J.3
  • 16
    • 62349138180 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients
    • M. Boschmann, S. Engeli, and K. Dobberstein et al. Dipeptidyl-peptidase- IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients J Clin Endocrinol Metab 94 2009 846 852
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 846-852
    • Boschmann, M.1    Engeli, S.2    Dobberstein, K.3
  • 17
    • 0035511643 scopus 로고    scopus 로고
    • Recent findings in the study of postprandial lipemia
    • E.J. Parks Recent findings in the study of postprandial lipemia Curr Atheroscler Rep 3 6 2001 462 470
    • (2001) Curr Atheroscler Rep , vol.3 , Issue.6 , pp. 462-470
    • Parks, E.J.1
  • 18
    • 84870294666 scopus 로고    scopus 로고
    • Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp an oral fat load
    • G. Derosa, A.F. Cicero, and E. Fogari et al. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp an oral fat load J Clin Lipidol 6 6 2012 553 564
    • (2012) J Clin Lipidol , vol.6 , Issue.6 , pp. 553-564
    • Derosa, G.1    Cicero, A.F.2    Fogari, E.3
  • 19
    • 80051703255 scopus 로고    scopus 로고
    • Effects of n-3 PUFAs on insulin resistance after an oral fat load
    • G. Derosa, A.F.G. Cicero, and E. Fogari et al. Effects of n-3 PUFAs on insulin resistance after an oral fat load Eur J Lipid Sci Technol 113 8 2011 950 960
    • (2011) Eur J Lipid Sci Technol , vol.113 , Issue.8 , pp. 950-960
    • Derosa, G.1    Cicero, A.F.G.2    Fogari, E.3
  • 20
    • 79958861430 scopus 로고    scopus 로고
    • Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load
    • G. Derosa, A.F. Cicero, and E. Fogari et al. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load Horm Metab Res 43 7 2011 505 512
    • (2011) Horm Metab Res , vol.43 , Issue.7 , pp. 505-512
    • Derosa, G.1    Cicero, A.F.2    Fogari, E.3
  • 21
    • 79959997617 scopus 로고    scopus 로고
    • Acarbose on insulin resistance after an oral fat load: A double-blind, placebo controlled study
    • G. Derosa, P. Maffioli, and A. D'Angelo et al. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study J Diabetes Complications 25 4 2011 258 266
    • (2011) J Diabetes Complications , vol.25 , Issue.4 , pp. 258-266
    • Derosa, G.1    Maffioli, P.2    D'Angelo, A.3
  • 22
    • 78650679019 scopus 로고    scopus 로고
    • Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load
    • G. Derosa, P. Maffioli, and I. Ferrari et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load Eur J Pharmacol 651 1-3 2011 240 250
    • (2011) Eur J Pharmacol , vol.651 , Issue.13 , pp. 240-250
    • Derosa, G.1    Maffioli, P.2    Ferrari, I.3
  • 23
    • 66149148712 scopus 로고    scopus 로고
    • Oral fat load effects on inflammation and endothelial stress markers in healthy subjects
    • G. Derosa, I. Ferrari, and A. D'Angelo et al. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects Heart Vessels 24 3 2009 204 210
    • (2009) Heart Vessels , vol.24 , Issue.3 , pp. 204-210
    • Derosa, G.1    Ferrari, I.2    D'Angelo, A.3
  • 24
    • 77749246297 scopus 로고    scopus 로고
    • Candesartan effect on inflammation in hypertension
    • G. Derosa, P. Maffioli, and S.A. Salvadeo et al. Candesartan effect on inflammation in hypertension Hypertens Res 33 3 2010 209 213
    • (2010) Hypertens Res , vol.33 , Issue.3 , pp. 209-213
    • Derosa, G.1    Maffioli, P.2    Salvadeo, S.A.3
  • 25
    • 77953536451 scopus 로고    scopus 로고
    • Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects
    • G. Derosa, I. Ferrari, and A. D'Angelo et al. Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects Microvasc Res 80 1 2010 110 115
    • (2010) Microvasc Res , vol.80 , Issue.1 , pp. 110-115
    • Derosa, G.1    Ferrari, I.2    D'Angelo, A.3
  • 26
    • 33846414720 scopus 로고    scopus 로고
    • Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    • L. Rydén, E. Standl, and M. Bartnik et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 1 2007 88 136
    • (2007) Eur Heart J , vol.28 , Issue.1 , pp. 88-136
    • Rydén, L.1    Standl, E.2    Bartnik, M.3
  • 27
    • 33749065167 scopus 로고    scopus 로고
    • Summary of American Heart Association diet and lifestyle recommendations revision 2006
    • A.H. Lichtenstein, L.J. Appel, and M. Brands et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006 Arterioscler Thromb Vasc Biol 26 2006 2186 2191
    • (2006) Arterioscler Thromb Vasc Biol , vol.26 , pp. 2186-2191
    • Lichtenstein, A.H.1    Appel, L.J.2    Brands, M.3
  • 28
    • 0017835519 scopus 로고
    • The glycosylation of haemoglobin. Relevance to diabetes mellitus
    • H.F. Bunn, K.H. Gabbay, and P.M. Gallop The glycosylation of haemoglobin. Relevance to diabetes mellitus Science 200 1978 21 27
    • (1978) Science , vol.200 , pp. 21-27
    • Bunn, H.F.1    Gabbay, K.H.2    Gallop, P.M.3
  • 29
    • 0032887833 scopus 로고    scopus 로고
    • A desktop guide to type 2 diabetes mellitus
    • European Diabetes Policy Group
    • European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabet Med 16 1999 716 730
    • (1999) Diabet Med , vol.16 , pp. 716-730
  • 30
    • 0015376786 scopus 로고
    • Determination of total serum insulin (IRI) in insulin-treated diabetic patients
    • L.G. Heding Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
    • (1972) Diabetologia , vol.8 , pp. 260-266
    • Heding, L.G.1
  • 31
    • 0021813187 scopus 로고
    • Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
    • D.R. Matthews, J.P. Hosker, and A.S. Rudenski et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
    • (1985) Diabetologia , vol.28 , pp. 412-419
    • Matthews, D.R.1    Hosker, J.P.2    Rudenski, A.S.3
  • 33
    • 0017358973 scopus 로고
    • Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II)
    • S. Klose, and K. Borner Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II) J Clin Chem Clin Biochem 15 1978 121 130
    • (1978) J Clin Chem Clin Biochem , vol.15 , pp. 121-130
    • Klose, S.1    Borner, K.2
  • 35
    • 33745026603 scopus 로고
    • The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
    • R.J. Havel, H.A. Edr, and J.H. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 34 1955 1345 1353
    • (1955) J Clin Invest , vol.34 , pp. 1345-1353
    • Havel, R.J.1    Edr, H.A.2    Bragdon, J.H.3
  • 36
    • 0015348189 scopus 로고
    • Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge
    • W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
    • (1972) Clin Chem , vol.18 , pp. 499-502
    • Friedewald, W.T.1    Levy, R.I.2    Fredrickson, D.S.3
  • 37
    • 0031833298 scopus 로고    scopus 로고
    • First direct assay for intact human proinsulin
    • P. Houssa, B. Dinensen, and M. Deberg et al. First direct assay for intact human proinsulin Clin Chem 44 7 1998 1514 1519
    • (1998) Clin Chem , vol.44 , Issue.7 , pp. 1514-1519
    • Houssa, P.1    Dinensen, B.2    Deberg, M.3
  • 38
    • 0020456354 scopus 로고
    • Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin
    • J.J. Holst Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin Biochem J 207 1982 381 388
    • (1982) Biochem J , vol.207 , pp. 381-388
    • Holst, J.J.1
  • 39
    • 0038359739 scopus 로고    scopus 로고
    • Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans
    • M. Yannakoulia, N. Yiannakouris, and S. Blüher et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans J Clin Endocrinol Metab 88 4 2003 1730 1736
    • (2003) J Clin Endocrinol Metab , vol.88 , Issue.4 , pp. 1730-1736
    • Yannakoulia, M.1    Yiannakouris, N.2    Blüher, S.3
  • 40
    • 34447118227 scopus 로고    scopus 로고
    • Retinol binding protein-4 levels and clinical features of type 2 diabetes patients
    • K. Takebayashi, M. Suetsugu, and S. Wakabayashi et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients J Clin Endocrinol Metab 92 7 2007 2712 2719
    • (2007) J Clin Endocrinol Metab , vol.92 , Issue.7 , pp. 2712-2719
    • Takebayashi, K.1    Suetsugu, M.2    Wakabayashi, S.3
  • 41
    • 23044473651 scopus 로고    scopus 로고
    • Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity
    • K. Hida, J. Wada, and J. Eguchi et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity Proc Natl Acad Sci U S A 102 2005 10610 10615
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 10610-10615
    • Hida, K.1    Wada, J.2    Eguchi, J.3
  • 42
    • 36849020047 scopus 로고    scopus 로고
    • Molecular characteristics of serum visfatin and differential detection by immunoassays
    • A. Korner, A. Garten, and M. Bluher et al. Molecular characteristics of serum visfatin and differential detection by immunoassays J Clin Endocrinol Metab 92 2007 4783 4791
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 4783-4791
    • Korner, A.1    Garten, A.2    Bluher, M.3
  • 43
    • 0018520840 scopus 로고
    • Glucose clamp technique, a method for quantifying insulin secretion and resistance
    • R.A. De Fronzo, J.A. Tobin, and B. Andres Glucose clamp technique, a method for quantifying insulin secretion and resistance Am J Physiol 237 1979 214 223
    • (1979) Am J Physiol , vol.237 , pp. 214-223
    • De Fronzo, R.A.1    Tobin, J.A.2    Andres, B.3
  • 44
    • 0023191508 scopus 로고
    • Insulin resistance in essential hypertension
    • E. Ferrannini, G. Buzzigoli, and R. Bonadonna et al. Insulin resistance in essential hypertension N Engl J Med 317 6 1987 350 357
    • (1987) N Engl J Med , vol.317 , Issue.6 , pp. 350-357
    • Ferrannini, E.1    Buzzigoli, G.2    Bonadonna, R.3
  • 46
    • 84861406329 scopus 로고    scopus 로고
    • Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients
    • H.J. Jeon, and T.K. Oh Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients Diabetes Metab J 35 5 2011 529 535
    • (2011) Diabetes Metab J , vol.35 , Issue.5 , pp. 529-535
    • Jeon, H.J.1    Oh, T.K.2
  • 47
    • 84876785125 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency
    • J.C. Arjona Ferreira, M. Marre, and N. Barzilai et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 36 5 2013 1067 1073
    • (2013) Diabetes Care , vol.36 , Issue.5 , pp. 1067-1073
    • Arjona Ferreira, J.C.1    Marre, M.2    Barzilai, N.3
  • 48
    • 84887204684 scopus 로고    scopus 로고
    • Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
    • Y.L. He, G. Foteinos, and S. Neelakantham et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring Diabetes Obes Metab 15 12 2013 1111 1119
    • (2013) Diabetes Obes Metab , vol.15 , Issue.12 , pp. 1111-1119
    • He, Y.L.1    Foteinos, G.2    Neelakantham, S.3
  • 49
    • 0036615275 scopus 로고    scopus 로고
    • The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes
    • R.N. Bergman, D.T. Finegood, and S.E. Kahn The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes Eur J Clin Invest 32 3 2002 35 45
    • (2002) Eur J Clin Invest , vol.32 , Issue.3 , pp. 35-45
    • Bergman, R.N.1    Finegood, D.T.2    Kahn, S.E.3
  • 50
    • 65549109984 scopus 로고    scopus 로고
    • Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
    • J. Rosenstock, M. Niggli, and M. Maldonado-Lutomirsky Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus Diabetes Obes Metab 11 6 2009 571 578
    • (2009) Diabetes Obes Metab , vol.11 , Issue.6 , pp. 571-578
    • Rosenstock, J.1    Niggli, M.2    Maldonado-Lutomirsky, M.3
  • 51
    • 84895529499 scopus 로고    scopus 로고
    • Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: A 2-year study evaluation
    • G. Derosa, P.D. Ragonesi, and E. Fogari et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation Fundam Clin Pharmacol 28 2 2014 221 229
    • (2014) Fundam Clin Pharmacol , vol.28 , Issue.2 , pp. 221-229
    • Derosa, G.1    Ragonesi, P.D.2    Fogari, E.3
  • 52
    • 33746690405 scopus 로고    scopus 로고
    • Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
    • N. Matikainen, S. Mänttäri, and A. Schweizer et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 9 2006 2049 2057
    • (2006) Diabetologia , vol.49 , Issue.9 , pp. 2049-2057
    • Matikainen, N.1    Mänttäri, S.2    Schweizer, A.3
  • 53
    • 23844463766 scopus 로고    scopus 로고
    • Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
    • A. Mari, W.M. Sallas, and Y.L. He et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes J Clin Endocrinol Metab 90 8 2005 4888 4894
    • (2005) J Clin Endocrinol Metab , vol.90 , Issue.8 , pp. 4888-4894
    • Mari, A.1    Sallas, W.M.2    He, Y.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.